Advertisement

GSK to produce 1 billion doses of COVID-19 vaccine booster

By
Don Jacobson
We believe that more than one vaccine will be needed ... and we are working with partners around the world to do so, a GSK executive said. File Photo by EPA-EFE
"We believe that more than one vaccine will be needed ... and we are working with partners around the world to do so," a GSK executive said. File Photo by EPA-EFE

May 28 (UPI) -- British pharmaceutical company GlaxoSmithKline announced Thursday its plans to make 1 billion doses of a vaccine booster system to aid development of potential COVID-19 vaccine candidates.

The use of a booster, or adjuvant, can reduce the amount of vaccine protein required per dose. GSK said it aims to deliver the doses through 2021.

Advertisement

"GSK believes that its pandemic adjuvant technology could make a significant contribution against COVID-19," the company said.

"As demonstrated in the last flu pandemic, GSK's pandemic adjuvant can reduce the amount of vaccine protein required per dose, which allows more vaccine doses to be produced, contributing to protecting more people."

RELATED Merck working with non-profit to develop COVID-19 vaccine

Adjuvants can also enhance immune response and have been shown to create a stronger and longer-lasting immunity against infections.

GSK struck a deal last month to provide its adjuvant technology for a COVID-19 vaccine candidate now under development by French pharma Sanofi. The company said Thursday, however, it will also provide the technology to any potential vaccine at its own financial risk.

"We believe that more than one vaccine will be needed to address this global pandemic and we are working with partners around the world to do so," Roger Connor, president of GSK Global Vaccines, said in a statement.

Advertisement
RELATED Novavax says COVID-19 vaccine candidate in clinical trials

"We believe that our innovative pandemic adjuvant technology has the potential to help improve the efficacy and scale up of multiple COVID-19 vaccines."

GSK said it will expand adjuvant manufacturing sites in Britain, the United States, Canada and Europe for the effort.

"With this significant expansion in our manufacturing capacity, we can help deliver up to 1 billion doses of adjuvanted vaccines through 2021, helping protect many more people and support the global effort to fight COVID-19," Connor added.

RELATED Vaccine for COVID-19 safe, effective in first human clinical trial, study says

Scenes from a pandemic: World copes with COVID-19

A health worker with the Israeli national emergency service, Magen David Adam, wears protective gear while taking swabs to test for COVID-19 at a drive-through testing center in East Jerusalem on August 26. Photo by Debbie Hill/UPI | License Photo

Latest Headlines